A treatment designed to strengthen a structurally weak cornea was not expected to become an antimicrobial therapy. Yet that is precisely the path that led to PACK-CXL.
When strengthening the cornea became a way to fight infection
Mark Hillen
A treatment designed to strengthen a structurally weak cornea was not expected to become an antimicrobial therapy. Yet that is precisely the path that led to PACK-CXL.